Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enlivex (ENLV) can continue enrollment as planned in its Phase IIb Allocetra knee osteoarthritis trial after an independent interim safety review. The Data and Safety Monitoring Board reviewed data from 85 patients who were randomly assigned and dosed. Enlivex's chief medical officer said the interim findings appeared consistent with the safety profile observed in the earlier Phase I/IIa trial.
The placebo-controlled trial (NCT07580716) plans to enroll approximately 182 patients in the United States, Denmark and Poland. It evaluates three injections into the joint in patients aged 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis. The trial measures changes from baseline in pain and physical function versus placebo at three and six months after treatment.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.Independent interim safety review of 85 randomized and dosed patients supports continued Phase IIb enrollment as planned
- Minor pointInterim safety findings appeared consistent with the earlier Phase I/IIa safety profile, Enlivex's chief medical officer said
Negative
- None.
Key Figures
- Patients in interim review
- 85 patients
- Randomized and dosed in the Phase IIb trial
- Planned enrollment
- approximately 182 patients
- Phase IIb trial
Previous Clinical trial Reports
-
Phase IIa results reported no treatment-related serious adverse events and a favorable safety profile.
-
Prior update reported 135 patients randomized in the same Phase IIb trial; 182 were planned.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
data and safety monitoring board medical
intra-articular medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nes-Ziona, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company's randomized, double-blind, placebo-controlled Phase IIb trial evaluating Allocetra™ in patients with primary age-related knee osteoarthritis has completed an interim safety review of data from 85 patients randomized and dosed in the trial. Following review of the data, the DSMB confirmed that the safety profile of Allocetra™ allows the Company to continue enrolling patients in the trial as planned.
“The outcome of this interim review, covering 85 patients randomized and dosed in the trial, appears consistent with the favorable safety profile observed in our Phase I/IIa trial,” said Einat Galamidi, Chief Medical Officer of Enlivex. “We are pleased with the DSMB’s decision that the trial will continue as planned and designed, and we remain focused on executing the Phase IIb trial and look forward to reporting topline data.”
About the Phase IIb Trial
The Phase IIb trial (NCT07580716), is a randomized, double-blind, placebo-controlled, global, multicenter, clinical trial which is designed to evaluate the efficacy and safety of 3 intra-articular injections of Allocetra™ in patients 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis. The trial is planned to enroll approximately 182 patients from clinical centers in the United States, Denmark and Poland. Key efficacy endpoints include changes from baseline of pain and physical function compared with placebo, measured at three- and six-month periods following treatment. Additional endpoints include changes in quality-of-life measures, functional mobility assessments and one year follow-up.
About Knee Osteoarthritis
Osteoarthritis (OA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to continue to grow substantially, with knee OA (KOA) being the most prevalent form. There are currently no approved disease-modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly
About Enlivex
Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain Protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.
Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.
Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk that results from subgroup analyses and small patient populations, including those described in this press release, may not be replicated in larger trials, including the Company's ongoing Phase IIb trial; the risk that topline data may change following a more comprehensive review of the data; the risk that RMAT designation may not lead to a faster development or regulatory review process and does not increase the likelihood of approval; risks related to the timing, conduct and outcome of clinical trials and regulatory submissions; the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.
Enlivex contact
Shachar Shlosberger
CFO
Enlivex Ltd.
shachar@enlivex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.